Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
fda
4
×
indiana blog main
4
×
life sciences
national blog main
new york blog main
biotech
boston blog main
boston top stories
indiana top stories
new york top stories
raleigh-durham blog main
san diego blog main
san francisco blog main
seattle blog main
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
eli lilly
europe blog main
europe top stories
national
national top stories
raleigh-durham top stories
san diego top stories
san francisco top stories
seattle top stories
texas blog main
texas top stories
type 1 diabetes
wisconsin blog main
wisconsin top stories
alnylam pharmaceuticals
ambys medicines
amicus therapeutics
ampio pharmaceuticals
angelman syndrome
arena pharmaceuticals
What
patients
4
×
drug
fda
diabetes
approval
aren’t
beta
bid
bio
bionics
blood
boehringer
cancer
closed
developers
developing
device
driven
drugs
eisai
eli
expand
fallen
flags
gene
heads
help
higher
imminent
incidence
ingelheim
key
levels
lilly
long
lorcaserin
loss
manages
market
marketed
Language
unset
Current search:
patients
×
fda
×
" indiana blog main "
×
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More